SGLT2 HYPE

A project for improving hypertension treatment

Hypertension, a leading cause of serious heart and kidney diseases, affects over 80 million people in the EU and contributes to one million deaths annually. Despite the availability of treatments, many patients continue to face significant health risks due to inadequate blood pressure control.

SGLT2 inhibitors, a class of drugs commonly used for diabetes and heart failure, have shown potential in lowering blood pressure and providing organ protection due to pleiotropic effects. However, research is required to confirm their effectiveness in hypertension management. SGLT2 HYPE aims to address this evidence gap to improve the prognosis of millions of patients with hypertension.

Learn more about the project

A project for improving hypertension treatment

News & Events

New EU-funded Project Aims to Transform Hypertension Treatment

Apr 5, 2025 | Press release

SGLT2 HYPE is a guideline-relevant clinical trial aiming to establish SGLT2 inhibitors as a new standard in high blood pressure therapy, ultimately addressing one of the leading causes of premature mortality in Europe

“The SGLT2 HYPE study offers a unique opportunity to generate new, evidence-based insights for hypertension treatment. It has the potential to provide millions of patients with a safer and more effective therapy.”

Prof. Ingo Eitel, Coordinator
Director of the Department of Internal Medicine II at UKSH, Campus Lübeck

“Hypertension is one of the greatest global health challenges, and there is an urgent need for new and effective treatment approaches. By participating in the SGLT2-HYPE study, we aim to contribute to generating robust scientific evidence that will enhance our understanding of the role of SGLT2 inhibitors in hypertension therapy.”

Dr. Elias Rawish, Coordinating Investigator
Department of Internal Medicine II at UKSH, Campus Lübeck